Covis Pharma is a global specialty pharmaceutical company

 

Our patients are our paramount concern. We market therapeutic solutions for patients with life-threatening conditions and chronic illnesses

Team

Covis is led by one of the strongest and longest-tenured senior management teams committed to delivering therapeutic solutions to improve the lives of its patients.

Strategic partners

Through its operational excellence, Covis is the preferred partner to world-class pharmaceutical companies and contract manufacturing organizations.

Product portfolio

Covis offers a portfolio of pharmaceutical products providing patients with affordable and therapeutically equivalent medications of select brands.

At Covis, our paramount concern is patients’ outcomes as we focus on improving the health of people with serious medical conditions.

Covis is always evaluating products and corporate acquisition opportunities. Covis is well-capitalized and has significant resources committed from its equity sponsors for tack-on deals and larger transaction opportunities.

 

Click here to access our California Compliance Statement and Declaration.

Company and product history

Founded by Cerberus Capital Management in 2011, the investment management firm with over $30 billion in assets under management.
2018:
Covis Pharma acquired Global rights for Alvesco®, Omnaris®, and Zetonna®.
2020:
Acquired by Apollo Global Management, Covis Pharma Group completed the acquisition of AMAG pharmaceuticals.
2022:
Covis Strengthens Global Respiratory Portfolio Through Acquisition of Two Medicines from AstraZeneca

The product information on this website is intended only for residents of the United States.
The products discussed herein may have different labeling in different countries.
© Copyright 2017-2021 Covis Pharma. All rights reserved.

Skip to content